NTRB - NASDAQ

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%

HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.45M

EPS-0.9900

P/E Ratio-4.19

Earnings Date04/27/2026

ntrb

Long Term Debt

Last Annual Value

58.20K

3-Year CAGR

-17%

5-Year CAGR

10-Year CAGR

56%

Adjust for Inflation

Nutriband Inc. Competitors Analysis of Long Term Debt

NTRB · NASDAQ

Company	Long Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Nutriband Inc. NASDAQ:NTRB	58.20K	-10.0%	-10.5%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	32.53M	6.8%	N/A	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	0.00	N/A	N/A	N/A
XBiotech Inc. NASDAQ:XBIT	0.00	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	1.54M	N/A	N/A	N/A
Adicet Bio, Inc. NASDAQ:ACET	0.00	N/A	N/A	N/A
Gain Therapeutics, Inc. NASDAQ:GANX	300.08K	-12.6%	-12.7%	N/A
MindWalk Holdings Corp. NASDAQ:HYFT	0.00	N/A	N/A	N/A
Vaxart, Inc. NASDAQ:VXRT	6.01M	31.8%	-10.9%	50.6%
ImageneBio Inc NASDAQ:IMA	7.02M	N/A	N/A	N/A
Immunic, Inc. NASDAQ:IMUX	107.00K	N/A	N/A	N/A

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

HIDDEN

Intrinsic Value

Current Price: $4.15

Related Guides

Blog Categories

Continue your NTRB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.